Answers are grounded in this paper and cite their sources.
In the past decade, ‘personalized’ or ‘stratified’ management based on the molecular features of tumors of patients with advanced non-small-cell lung cancer (NSCLC) has entered routine clinical practice. Identification on tumor tissue of predictive biomarkers of response to targeted treatments is now mandatory for optimal patient care, but faces several biological and technological challenges.
No takes yet. Share an insight, caveat, or question.
Ilié et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: